Inspection Record

Allergy Laboratories, Inc. — FDA 483 Findings

US FDAInspected 2015-07-23Published 2024-01-17 24 findingsEnvironmental monitoringTraining and personnelRegulatory reporting and change controlAseptic processing and sterility assuranceOther quality systemContamination controlDeviation, CAPA, and investigationMaterial and supplier controlStability and storageCleaning validationLabeling and packagingEquipment and facilityValidation and qualification

View the regulator's official source The source document is always the basis for judgement.

Findings

1Environmental monitoring

Investigations into environmental monitoring excursions are inadequate and/or inappropriate Environmental Notices (EN) are the investigations that take place when tbe firm experiences either alert or action limits for p ersonnel, active air, and surface monitoring.

2Training and personnel

Operators working in the filling suites monitor their own gloves and garments after working in the area.

3Regulatory reporting and change control

The firm's change control program is not followed.

4Aseptic processing and sterility assurance

Actions taken regarding non-viable particulate excursions that occur during aseptic filling on RED ACTION (b)(4) are inadequate.

5Other quality system

Stoppers used with allergenic extract R EDACTION (b)(4) glycerin) final product vials have not been demonst rated to be non reactive, additive, or absorptive.

6Environmental monitoring

Growth promotion testing for environmental monitoring plates is not performed in a manner to chal leng e the test plate in that the firm's SOP for growth promotion testing allows for incubation of plates for up to REDACTION (b)(4)

7Other quality system

Non-viable particulate excursion alanns are not reacted to in real time.

8Contamination control

Product impact is not adequately addressed for incidences where contamination occurs on product contact services.

9Aseptic processing and sterility assurance

Since 11/15/12 the firm has experienced sterility failures for 9 commercial products .

10Deviation, CAPA, and investigation

The investigation conducted under PACAR PAC-021-081312 did not include a product impact assessment.

11Aseptic processing and sterility assurance

Smoke studies performed on Line REDACTION (b)(4) in Building REDACTION (b)(4) revealed the following: A.

12Material and supplier control

The firm's supplier ofanimals which are used for the general safety testing of allergenic extracts has not been

13Aseptic processing and sterility assurance

SOP QC-033.00, Facility Bioburden, section 9.1.3 requires that "All environmental isolates are sent out for identification, including alert and action level samples, routine bioburden samples, media fill samples and Class 100 samples, shall be identified to the species-level".

14Other quality system

The firm's routine process to REDACTION (b)(4).

15Stability and storage

No limits have been established for the amount of time allergenic extracts may be exposed to ambient temperature during filling, inspection, labeling and packaging, packing for shipping.

16Cleaning validation

SOP MFG-031.01 "Cleaning Procedure for Vial Production Areas" does not contain sufficient detail e xplaining how filling equipment is to be cleaned.

17Aseptic processing and sterility assurance

There is a lack of assurance in the environmental quality in Class 100 aseptic processing areas in that the fir m does not perform adequate environmental monitoring within these areas .

18Labeling and packaging

The 100% visual inspection of REDACTION (b)(4) products filled on Line REDACTION (b)(4) is performed prior to REDACTION (b)(4) Only a cursory inspecti on of the units during REDACTION (b)(4) packaging is performed post REDACTION (b)(4) and labeling .

19Aseptic processing and sterility assurance

Aseptic processing deficiencies include: A.

20Equipment and facility

The following facility and equipment maintenance issues were observed: A.

21Validation and qualification

The number of qualified personnel is inadequate to supervise the manufacture of Allergenic Extract produc ts.Personnel engaged in manufacture of allergenic products have no definitive assigned supervisor.

22Other quality system

The firm's procedures allow the release of allergenic extracts exhibiting cloudiness.

23Aseptic processing and sterility assurance

There is a Jack of assurance that limits set in the aseptic processing area are adequate.

24Labeling and packaging

Driving the labeling of Phenylephrine HCI injection Lot 042413 the vials after inspection and labeling were observed traveling down a REDAC TION (b)(4) from the REDACTION (b)(4) and t hen dropping into a bin.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Allergy Laboratories, Inc. company profile — full history US FDA documents, 2024 Go to Findings search